Assessment of the roche linear array hpv genotyping test within the valgent framework
In 2012, the International Agency for Research on Cancer (IARC) concluded that at least 12 high-risk human papillomavirus (hrHPV) types (HPV16, HPV18, HPV31, HPV33, HPV35, HPV3, HPV45, HPV51, HPV52, HPV56, HPV58 and HPV59), were carcinogenic to humans for the development of cervical cancer (IARC-2009 hrHPV types)[1]. Furthermore, it has been demonstrated through several randomized controlled trials that hrHPV DNA testing is more effective than cervical cytology in primary screening of women aged 30 years or older [2,3].
Source: Journal of Clinical Virology - Category: Virology Authors: Lan Xu, Anja O štrbenk, Mario Poljak, Marc Arbyn Source Type: research
More News: Cancer | Cancer & Oncology | Cervical Cancer | Cytology | Genital Warts | HPV Testing | Human Papillomavirus (HPV) | Virology | Women